Sandberg David E, Voss Linda D
Pediatric Psychiatry and Physiology, The Children's Hospital of Buffalo, 219 Bryant Street, Buffalo, NY 14222, USA.
Best Pract Res Clin Endocrinol Metab. 2002 Sep;16(3):449-63. doi: 10.1053/beem.2002.0211.
The advent of biosynthetic growth hormone (GH) has been accompanied by a transformation in the clinical management of youths with short stature. An important--if not always explicitly stated--goal of endocrine therapies is an improvement in the psychological adaptation of individuals with short stature. Negative stereotypes regarding short stature constitute a potential source of psychosocial stress for the affected child and, in turn, the entire family. Nevertheless, studies have demonstrated that the psychological adaptation of individuals who are shorter than average is largely indistinguishable from others, whether in childhood, adolescence or adulthood. "Short stature" as an isolated physical characteristic appears to hold little value as a predictor of the individual's psychological adaptation or quality of life. In order to avoid the unwarranted medicalizing of healthy short stature, clinicians would be well advised to incorporate factors beyond auxology in the decision-making algorithm when selecting and preparing patients for possible growth-promoting therapies.
生物合成生长激素（GH）的出现，伴随着对身材矮小青少年临床管理的变革。内分泌治疗的一个重要目标（即便并非总是明确表述）是改善身材矮小个体的心理适应能力。关于身材矮小的负面刻板印象，是受影响儿童乃至整个家庭潜在的心理社会压力源。然而，研究表明，身材低于平均水平的个体，无论在儿童期、青春期还是成年期，其心理适应能力与其他人在很大程度上并无差异。“身材矮小”作为一个孤立的身体特征，似乎对个体的心理适应能力或生活质量几乎没有预测价值。为避免对健康的身材矮小进行不必要的医学化处理，临床医生在为可能的促生长治疗选择和准备患者时，最好在决策算法中纳入身高学以外的因素。
